by Richard Daverman, PhD
September 16, 2013 -- Wanbang Biopharmaceuticals, a subsidiary of Shanghai Fosun Pharma, received CFDA to begin clinical trials of a third-generation insulin analogue, Lispro. Lispro is a recombinant insulin that is designed to be fast-acting, with a relatively short duration of action, usually taken just before, or just after mealtimes. In China, only Lilly and Gan & Lee offer Lispro-class insulin drugs. More details....
Stock Symbols: (SHA: 600196, HK: 2196) (NYSE: LLY)
Help employers find you! Check out all the jobs and post your resume.
